Docket #: S22-104
Synthetic Transcription Elongation Factors to Target Mutations in Cancer Genomes
Researchers at Stanford have developed synthetic transcription elongation factors (Syn-TEFs) to treat proliferative diseases, including repeat expansion mutations in cancer. Repeat expansions are believed to contribute to cancer proliferation but many are considered untreatable by available therapeutics. Syn-TEFs have previously been shown to treat devastating neurodegenerative diseases. The newly reported Syn-TEFs are bifunctional compounds that specifically target GAAA repeats linked to cancer. They consist of a pyrrole/imidazole polyamide and a bromodomain inhibitor, and have demonstrated anti-proliferative effects in kidney cancer in vitro. This work supports the development of personalized therapies that target cancer DNA mutations directly. Since Syn-TEFs are modular in nature, the DNA-binding polyamide can easily be modified to target any DNA sequence of interest, including any repeat expansions identified in cancer.
Stage of Development
The researchers have demonstrated anti-proliferative activity in cancer cell lines.
Applications
- Small molecule development in oncology
Advantages
- Many repeat expansions considered untreatable by available therapeutics.
- Syn-TEFs are targeted and modular, allowing the DNA-binding polyamide to be modified.
- Can be used as a template for personalized anti-cancer therapy.
Related Links
Patents
- Published Application: 20230322853
Similar Technologies
-
First Report of Small Molecule inhibitors of Histone Acetyltransferase 1 (HAT1) with Anti-Tumor Activity S21-166First Report of Small Molecule inhibitors of Histone Acetyltransferase 1 (HAT1) with Anti-Tumor Activity
-
Molecules and methods for treatment of cancer with TCIPs S23-242Molecules and methods for treatment of cancer with TCIPs
-
CDK19- Selective Inhibitors, and Methods of Use thereof S20-084CDK19- Selective Inhibitors, and Methods of Use thereof